A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
Latest Information Update: 16 Aug 2024
At a glance
- Drugs JNJ-75348780 (Primary) ; JNJ-75348780 (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 02 Jan 2024 Planned End Date changed from 11 Sep 2026 to 9 May 2025.
- 05 Dec 2023 Planned primary completion date changed from 31 Oct 2023 to 4 Apr 2025.
- 10 Oct 2023 Status changed from recruiting to active, no longer recruiting.